目的 探討復(fù)方骨肽注射液聯(lián)合唑來膦酸治療胸腰椎骨質(zhì)疏松性骨折的臨床效果。方法 選取林州市人民醫(yī)院2015年5月-2017年10月收治的胸腰椎骨質(zhì)疏松性骨折患者152例，隨機(jī)分成對(duì)照組（76例）與治療組（76例）。對(duì)照組靜脈滴注唑來膦酸注射液，5 mg加入生理鹽水100 mL，1次/3周，連續(xù)治療4次。治療組在對(duì)照組基礎(chǔ)上靜脈滴注復(fù)方骨肽注射液，10 mL加入生理鹽水250 mL，1次/d，連用2周，停藥1周為1療程，共治療4個(gè)療程。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者疼痛視覺模擬評(píng)分法（VAS）、骨密度和骨代謝指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組臨床總有效率分別為81.58%、93.42%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療1、3個(gè)月后，兩組患者VAS評(píng)分均顯著下降（P<0.05）；且治療后治療組患者VAS評(píng)分明顯低于同期對(duì)照組患者（P<0.05）。治療1、3個(gè)月后，治療組骨密度比治療前明顯增加（P<0.05）；治療3個(gè)月后，對(duì)照組骨密度明顯增加（P<0.05）；治療3個(gè)月后，治療組患者骨密度均明顯高于同期對(duì)照組（P<0.05）。治療后，兩組血清骨鈣素（BGP）、骨堿性磷酸酶（BALP）水平較治療前均明顯上升（P<0.05）；且治療組比對(duì)照組上升更顯著（P<0.05）。結(jié)論 復(fù)方骨肽注射液聯(lián)合唑來膦酸治療胸腰椎骨質(zhì)疏松性骨折可有效緩解患者的疼痛程度，提高骨密度，改善骨代謝。

Objective To investigate the clinical effect of Compound Ossotide Injection combined with zoledronic acid in treatment of osteoporotic fracture of thoracolumbar vertebra. Methods Patients (152 cases) with osteoporotic fracture of thoracolumbar vertebra in Linzhou People's Hospital from May 2015 to October 2017 were randomly divided into control (76 cases) and treatment (76 cases) groups. Patients in the control group were iv administered with Zoledronic Acid Injection, 5 mg added into normal saline 100 mL, once every 3 weeks. Patients in the treatment group were iv administered with Compound Ossotide Injection on the basis of the control group, 10 mL added into normal saline 250 mL, once daily, Continuous use for 2 weeks and 1 week of drug withdrawal was as 1 course of treatment. Patients in two groups were treated for 4 treatment courses. After treatment, the clinical efficacy was evaluated, and the VAS scores, the bone density, and the bone metabolism indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.58% and 93.42%, respectively, and there were differences between two groups (P<0.05). After treatment for 1 and 3 months, the VAS scores in two groups were significantly decreased (P<0.05), and the VAS scores in the treatment group after treatment were significantly lower than that in the control group over the same period (P<0.05). After treatment for 1 and 3 months, the bone density in the treatment group was significantly increased (P<0.05). After treatment for 3 months, the bone density in the control group was significantly increased (P<0.05). After treatment for 3 months, the bone density in the treatment group was significantly higher than that in the control group over the same period (P<0.05). After treatment, the serum BGP and BALP levels in two groups were significantly increased (P<0.05), and the bone metabolism indicators in the treatment group after treatment were significantly higher than those in the control group (P<0.05). Conclusion Compound Ossotide Injection combined with zoledronic acid in treatment of osteoporotic fracture of thoracolumbar vertebra can effectively relieve the pain, increase the bone mineral density and ameliorate bone metabolism.